Company Profile: iCAD, Inc.
Background
iCAD, Inc., established in 1984 as Howtek, Inc., is a medical technology company headquartered in Nashua, New Hampshire, USA. The company specializes in AI-powered cancer detection solutions, focusing primarily on breast cancer detection, breast density assessment, and personalized risk evaluation. iCAD's mission is to create a world where cancer can't hide by providing innovative artificial intelligence solutions that empower healthcare providers to accurately, reliably, and quickly detect cancer, thereby improving patient outcomes. The company's vision is to optimize every patient's opportunity to live better, longer lives through advanced technology.
Key Strategic Focus
iCAD's strategic focus centers on developing and delivering AI-driven solutions for early cancer detection and risk assessment. The company's ProFound Breast Health Suite offers a comprehensive portfolio of clinically proven AI technologies for breast cancer detection, automated breast density assessment, and short-term personalized risk evaluation. These solutions are designed to seamlessly integrate into existing healthcare workflows, enhancing diagnostic accuracy and efficiency. iCAD's primary markets include hospitals, imaging centers, and healthcare providers across the United States and internationally.
Financials and Funding
As of July 16, 2025, iCAD's stock price was $3.87, with a market capitalization of approximately $56.37 million. The company reported a revenue of $19.53 million for the trailing twelve months, marking an 8.9% increase from the previous period. However, iCAD reported a net loss of $5.23 million during the same period. In April 2025, iCAD was acquired by DeepHealth, Inc., a wholly-owned subsidiary of RadNet, Inc., which may influence the company's future financial strategies and funding.
Pipeline Development
iCAD's primary product, the ProFound Breast Health Suite, is FDA-cleared, CE-marked, and Health Canada licensed. The suite includes solutions for breast cancer detection, breast density assessment, and personalized risk evaluation based on 2D or 3D mammogram images. These solutions are designed to integrate seamlessly into existing healthcare workflows, enhancing diagnostic accuracy and efficiency.
Technological Platform and Innovation
iCAD's technological platform leverages advanced artificial intelligence and image analysis to identify pathologies and detect prevalent cancers earlier. The company's ProFound Breast Health Suite utilizes deep learning algorithms to analyze mammogram images, providing healthcare providers with tools to improve diagnostic accuracy and patient outcomes. iCAD's solutions are backed by extensive, globally diverse, and rigorously validated datasets, ensuring reliability and effectiveness in various clinical settings.
Leadership Team
As of April 2025, the leadership team at iCAD includes:
- Dana R. Brown: President, Chief Executive Officer, and Executive Chair.
- Eric Lonnqvist: Chief Financial Officer.
- Jonathan Go: Chief Technology Officer.
- Michelle Strong: Chief Operations Officer.
- Annette L. Heroux: Vice President of Administration.
- Brian Testa: Chief People Officer.
- Bill Keyes: Senior Vice President of Global Sales Operations.
- Vasu Avadhanula: Chief Product Officer.
- Peter Graham: Senior Vice President of North American Sales.
- Mark Koeniguer: Chief Commercial Officer.
In April 2025, Mark Koeniguer was appointed as Chief Commercial Officer, a role that may influence iCAD's strategic direction and market expansion efforts.
Competitor Profile
Market Insights and Dynamics
The medical imaging and AI-powered cancer detection market is experiencing significant growth, driven by advancements in artificial intelligence, increasing demand for early cancer detection, and the need for efficient healthcare solutions. The market is characterized by rapid technological innovation and a growing emphasis on personalized medicine.
Competitor Analysis
iCAD operates in a competitive landscape with several key players:
- Aidoc: Offers clinical AI solutions for analyzing medical imaging, aiming to assist with workflow management and identifying key findings.
- Clairity: Utilizes artificial intelligence to enhance healthcare outcomes, particularly in precision medicine and early disease detection.
- Koios Medical: Provides AI-driven solutions for breast cancer detection, focusing on improving diagnostic accuracy and workflow efficiency.
These competitors offer similar AI-powered solutions for cancer detection, contributing to a dynamic and evolving market.
Strategic Collaborations and Partnerships
In March 2025, iCAD announced a partnership with RamSoft, a global leader in cloud-based imaging solutions, to deliver ProFound AI-powered mammography solutions across North America. This collaboration aims to enhance the integration and accessibility of iCAD's AI technologies in healthcare settings.
Operational Insights
iCAD's acquisition by DeepHealth, Inc., a subsidiary of RadNet, Inc., in April 2025, may provide the company with enhanced resources and capabilities to expand its market presence and accelerate the development of its AI-powered cancer detection solutions. This strategic move positions iCAD to leverage RadNet's extensive network and infrastructure in the healthcare sector.
Strategic Opportunities and Future Directions
Looking ahead, iCAD aims to expand its product offerings and market reach by leveraging its AI technologies to address a broader range of cancers and medical imaging applications. The company is focused on
